英文标题：Osimertinib (osi) with or without chemotherapy (CTx) as first-line treatment in EGFR-mutant (EGFRm) advanced NSCLC with concurrent TP53 mutations (TOP study)

中文标题：奥希替尼联合或不联合化疗一线治疗伴TP53共突变的EGFR突变晚期非小细胞肺癌（TOP研究）

讲者：杨云鹏 中山大学肿瘤防治中心

英文标题：Phase II Study of iza-bren (BL-B01D1) in Combination with Serplulimab in Patients with Small Cell Lung Cancer (SCLC)

中文标题：iza-bren (BL-B01D1) 联合斯鲁利单抗治疗小细胞肺癌 (SCLC) 的II期研究

讲者：周斐 同济大学附属东方医院

英文标题：Becotarug (JMT101) and Osimertinib (Osi) in Patients (pts) with Platinum-Pretreated EGFR Exon 20 Insertion-Mutated (ex20ins) Non-Small Cell Lung Cancer (NSCLC): Final Overall Survival (OS) and Subgroup Analyses from the BECOME Phase 2 Study

中文标题：Becotarug (JMT101) 联合奥希替尼治疗既往经含铂化疗的EGFR 20外显子插入突变非小细胞肺癌：BECOME II期研究的最终总生存期 (OS) 及亚组分析

讲者：张力 中山大学肿瘤防治中心

英文标题：Subcutaneous Versus Intravenous Toripalimab, in Combination with Chemotherapy, as a First-Line Treatment for Recurrent or Metastatic Non-Squamous (Nsq) Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase 3 Trial

中文标题：皮下对比静脉给予特瑞普利单抗联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌：一项随机III期临床试验

讲者：邬麟 湖南省肿瘤医院

英文标题：A first-in-human phase I study of TQB2922, an EGFR/C-MET bispecific antibody, as monotherapy and in combination with bevacizumab and chemotherapy in EGFR-mutant non-small cell lung cancer

中文标题：EGFR/c-MET双特异性抗体TQB2922单药以及联合贝伐珠单抗和化疗治疗EGFR突变非小细胞肺癌的首次人体I期研究

讲者：张力 中山大学肿瘤防治中心

英文标题：SHR-A2009, a HER3-targeted ADC, plus aumolertinib (A) as 1L or ≥2L treatment for EGFR-mutated (EGFRm) NSCLC: a phase 1b/2 study

中文标题：HER3靶向ADC药物SHR-A2009联合阿美替尼一线或二线及以上治疗EGFR突变非小细胞肺癌：一项Ib/II期研究

讲者：吴一龙 广东省人民医院

英文标题：First disclosure of efficacy and safety data for YL202/BNT326 (HER3 ADC) from a Phase 2 trial in patients (pts) with non-small cell lung cancer (NSCLC)

中文标题：YL202/BNT326 (HER3 ADC) 治疗非小细胞肺癌的II期试验疗效与安全性数据首次公布

讲者：刘海峰 吉林省肿瘤医院